Primary Percutaneous Coronary Intervention with High-Bolus Dose Tirofiban: The FASTER (Favorite Approach to Safe and Effective Treatment for Early Reperfusion) Multicenter Registry.
Journal
Journal of interventional cardiology
ISSN: 1540-8183
Titre abrégé: J Interv Cardiol
Pays: United States
ID NLM: 8907826
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
01
2022
revised:
04
03
2022
accepted:
10
03
2022
entrez:
14
4
2022
pubmed:
15
4
2022
medline:
16
4
2022
Statut:
epublish
Résumé
To investigate the safety and clinical efficacy of tirofiban during primary percutaneous coronary interventions (pPCI). Gp IIb/IIIa inhibitors (GPI) use during pPCI has declined over years, mainly for the increased hemorrhagic risk associated to their use and for the availability of potent, fast-acting oral antiplatelet drugs. However, several pharmacodynamic studies showed suboptimal platelet inhibition with P2Y12-blockers, such as prasugrel or ticagrelor. Patients with ST-segment elevation myocardial infarction (STEMI) undergoing pPCI were prospectively enrolled in a multicenter registry conducted in high-volume centers in Italy. All patients received intraprocedural tirofiban. The primary safety endpoint was the occurrence of in-hospital bleedings according to the Bleeding Academic Research Consortium definition. In-hospital major adverse coronary events (MACE, defined as death, reinfarction, stent thrombosis, and target vessel revascularization), final TIMI flow, myocardial blush grade, and ST-segment resolution were also evaluated. A total of 472 patients (mean age 61 ± 11 years, 83% males) were enrolled in 16 Italian centers from October 2015 to June 2018. Mean basal thrombus grade score was 3.47 ± 1.25. PCI was performed by transradial approach in 88% of patients. We observed a very low rate of 30 days BARC bleedings (2.1%) and MACE (0.8%). Complete (>70%) ST-segment resolution was observed in 67% of patients. In the FASTER registry, the use of tirofiban during primary PCI, performed with a transradial approach in most cases, in patients with high thrombus burden was associated with high rates of complete ST-segment resolution and low rates of in-hospital bleeding and MACE.
Sections du résumé
Objectives
UNASSIGNED
To investigate the safety and clinical efficacy of tirofiban during primary percutaneous coronary interventions (pPCI).
Background
UNASSIGNED
Gp IIb/IIIa inhibitors (GPI) use during pPCI has declined over years, mainly for the increased hemorrhagic risk associated to their use and for the availability of potent, fast-acting oral antiplatelet drugs. However, several pharmacodynamic studies showed suboptimal platelet inhibition with P2Y12-blockers, such as prasugrel or ticagrelor.
Methods
UNASSIGNED
Patients with ST-segment elevation myocardial infarction (STEMI) undergoing pPCI were prospectively enrolled in a multicenter registry conducted in high-volume centers in Italy. All patients received intraprocedural tirofiban. The primary safety endpoint was the occurrence of in-hospital bleedings according to the Bleeding Academic Research Consortium definition. In-hospital major adverse coronary events (MACE, defined as death, reinfarction, stent thrombosis, and target vessel revascularization), final TIMI flow, myocardial blush grade, and ST-segment resolution were also evaluated.
Results
UNASSIGNED
A total of 472 patients (mean age 61 ± 11 years, 83% males) were enrolled in 16 Italian centers from October 2015 to June 2018. Mean basal thrombus grade score was 3.47 ± 1.25. PCI was performed by transradial approach in 88% of patients. We observed a very low rate of 30 days BARC bleedings (2.1%) and MACE (0.8%). Complete (>70%) ST-segment resolution was observed in 67% of patients.
Conclusions
UNASSIGNED
In the FASTER registry, the use of tirofiban during primary PCI, performed with a transradial approach in most cases, in patients with high thrombus burden was associated with high rates of complete ST-segment resolution and low rates of in-hospital bleeding and MACE.
Identifiants
pubmed: 35418809
doi: 10.1155/2022/9609970
pmc: PMC8983258
doi:
Substances chimiques
Platelet Aggregation Inhibitors
0
Tyrosine
42HK56048U
Tirofiban
GGX234SI5H
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
9609970Informations de copyright
Copyright © 2022 Stefano Rigattieri et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest.
Références
Ann Pharmacother. 2020 May;54(5):414-422
pubmed: 31766865
N Engl J Med. 2014 Sep 11;371(11):1016-27
pubmed: 25175921
N Engl J Med. 2008 May 22;358(21):2218-30
pubmed: 18499566
Circulation. 2001 May 29;103(21):2550-4
pubmed: 11382722
N Engl J Med. 2007 Dec 13;357(24):2482-94
pubmed: 18077812
Thromb Res. 2016 Jul;143:141-8
pubmed: 27259210
Eur Heart J. 2009 Nov;30(22):2705-13
pubmed: 19875386
J Am Coll Cardiol. 2006 Dec 5;48(11):2178-85
pubmed: 17161242
Am J Cardiol. 2021 Jan 15;139:15-21
pubmed: 33065082
Circ Cardiovasc Interv. 2012 Dec;5(6):797-804
pubmed: 23169985
Lancet. 2015 Jun 20;385(9986):2465-76
pubmed: 25791214
Lancet. 2013 Dec 14;382(9909):1981-92
pubmed: 24011551
Eur Heart J. 2017 Apr 7;38(14):1069-1080
pubmed: 28329389
Circulation. 2020 Aug 4;142(5):441-454
pubmed: 32795098
Lancet. 2008 Aug 16;372(9638):537-46
pubmed: 18707985
JACC Cardiovasc Interv. 2012 Mar;5(3):268-77
pubmed: 22440491
N Engl J Med. 2009 Sep 10;361(11):1045-57
pubmed: 19717846
Curr Drug Targets. 2011 Nov;12(12):1831-5
pubmed: 21718235
J Am Heart Assoc. 2021 Jul 6;10(13):e022125
pubmed: 34212768
Circulation. 2009 Apr 14;119(14):1933-40
pubmed: 19332467
Curr Drug Targets. 2014;15(7):720-8
pubmed: 24845219
J Am Coll Cardiol. 2004 Jan 21;43(2):276-83
pubmed: 14736449
J Interv Cardiol. 2021 Jun 15;2021:9917407
pubmed: 34220370